This is interesting so far as it formally pubilshes a number of things that we really already knew. None of this information is really new, let alone surprising.
The current market cap makes it clear that anyone who is buying shares at this point is doing so with the hope that the drugs can succeed in spite of management's ineptitude. The future royalty rights that Nuvo has for Pennsaid (current version and 2%) and Pliaglis are worth more than $20 million. I don't think anyone familiar with those products could realistically argue otherwise. In other words, take those drugs away and the company is being priced with a negative value.